CTI BioPharma Corp.
CTIC · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $53,948 | $0 | $0 | $3,345 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $3,514 | $161 | $4,200 | $0 |
| Gross Profit | $50,434 | -$161 | -$4,200 | $3,345 |
| % Margin | 93.5% | – | – | 100% |
| R&D Expenses | $36,895 | $39,136 | $25,943 | $24,107 |
| G&A Expenses | $0 | $0 | $17,626 | $0 |
| SG&A Expenses | $84,826 | $56,196 | $17,626 | $19,155 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $8,510 | -$161 | $4,200 | $0 |
| Operating Expenses | $130,231 | $95,332 | $47,769 | $43,262 |
| Operating Income | -$79,797 | -$95,332 | -$47,769 | -$40,711 |
| % Margin | -147.9% | – | – | -1,217.1% |
| Other Income/Exp. Net | -$13,195 | -$2,576 | -$4,682 | $688 |
| Pre-Tax Income | -$92,992 | -$97,908 | -$52,451 | -$40,023 |
| Tax Expense | -$1,951 | $1,728 | $500 | $2,294 |
| Net Income | -$91,041 | -$99,636 | -$52,951 | -$42,317 |
| % Margin | -168.8% | – | – | -1,265.1% |
| EPS | -0.79 | -1.11 | -0.74 | -0.73 |
| % Growth | 28.8% | -50% | -1.4% | – |
| EPS Diluted | -0.79 | -1.11 | -0.74 | -0.73 |
| Weighted Avg Shares Out | 114,694 | 90,117 | 71,141 | 57,974 |
| Weighted Avg Shares Out Dil | 114,694 | 90,117 | 71,141 | 57,974 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,684 | $38 | $204 | $1,172 |
| Interest Expense | $13,139 | $2,415 | $1,032 | $1,523 |
| Depreciation & Amortization | -$56 | -$161 | $204 | $3,286 |
| EBITDA | -$79,853 | -$95,332 | -$51,215 | -$37,425 |
| % Margin | -148% | – | – | -1,118.8% |